Proteomics International Laboratories Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PIQ.AX research report →
Price Chart
About the company
Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and Southeast Asia. It provides PromarkerD, a blood test to predict diabetic kidney disease (DKD). The company’s products under development include PromarkerEndo, which has completed clinical validation phase for endometriosis diagnosis; PromarkerEso, which has completed clinical validation trials for esophageal cancer diagnosis; and OxiDx (2-tag), which has completed clinical validation phase for oxidative stress treatment.
- CEO
- David N. Morris
- IPO
- 2015
- Employees
- 161
- HQ
- Nedlands, WA, AU
Get TickerSpark's AI analysis on PIQ.AX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $27.29M
- P/E
- -2.45
- PEG
- 0.09
- P/S
- 56.79
- P/B
- 3.63
- EV/EBITDA
- -1.70
- Div Yield
- 0.00%
- Gross Margin
- -1927.07%
- Op Margin
- -2555.92%
- Net Margin
- -2009.67%
- ROE
- -93.66%
- ROIC
- -104.30%
Latest fiscal year · YoY change
- Revenue
- $960.39K+7.6%
- Gross Profit
- $960.39K+185.5%
- Op Income
- $-10,618,719
- Net Income
- $-8,114,797-27.3%
- EPS
- $-0.05-7.1%
- OCF Growth
- -18.1%
- FCF Growth
- -10.6%
- 52W High
- $0.86
- 52W Low
- $0.10
- 50D MA
- $0.15
- 200D MA
- $0.32
- Beta
- -0.34
- RSI (14)
- 54
- Avg Volume
- 398.24K
No earnings-call transcripts are available for PIQ.AX yet.
- Free Float
- 75.2%
- Shares Outstanding
- 165.37M
- Float Shares
- 124.29M
Our PIQ.AX coverage
Recent articles, reports, and earnings notes.
No research on PIQ.AX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PIQ.AX report →